Our services

ADC Review
is made possible by:

Celldex Prioritizes Development Pipeline – Discontinues ADC-development Programs

Published on 10th May

Earlier this year, in April, Celldex Therapeutics reported that the randomized, Phase IIb METRIC Study of glembatumumab vedotin, also known as CDX-011, a targeted antibody-drug conjugate or ADC, compared to capecitabine (Xeloda®; Genentech/Roche) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans. [1][2]

As a consequence, the company announced that, based on these results, the decision was made to discontinue the glembatumumab vedotin development program across all indications.

Schematic 1.0: The main purpose of the Phase II METRIC study was to see whether Glembatumumab Vedotin, an antibody-drug conjugate also known as CDX-011, is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which glembatumumab vedotin binds to. The study was also designed to further characterize the safety of CDX-011 treatment in this patient population.

Glembatumumab vedotin is a fully human monoclonal antibody-drug conjugate targeting glycoprotein NMB (gpNMB). This protein is overexpressed by multiple tumor types, including breast cancer, melanoma, lung cancer, uveal melanoma and osteosarcoma.

The gpNMB-targeting antibody, CR011, is linked to a potent cytotoxic, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary technology. Glembatumumab vedotin is designed to be stable in the bloodstream but to release MMAE upon internalization into gpNMB-expressing tumor cells, resulting in a targeted cell-killing effect.

Strategic prioritization
“Celldex has made considerable progress on an important strategic prioritization of our pipeline, following announcement in April of the METRIC study results in triple-negative breast cancer and discontinuation of the glembatumumab vedotin program across all indications,” commented Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics.

Following the discontinuation of the glembatumumab vedotin development program, the company announced that it will also cancel the ongoing development of CDX-014.  This ADC, which targets TIM-1, is currently in early Phase I development in renal cell and clear cell ovarian carcinomas.[2]

The investigational agent is designed to target the extracellular domain of the T cell immunoglobulin mucin domain 1 (TIM-1),  a type I transmembrane protein that was originally described as kidney injury molecule 1 (KIM-1) due to its elevated expression in kidney and urine after renal injury.

NCT02837991 (Clinical Trial/ CDX-014)
Schematic 2.0: The NCT02837991 study was designed to determine the safety and effectiveness of CDX-014. The study enrolled patients with advanced or metastatic renal cell carcinoma and ovarian clear cell carcinoma. This study included a Dose-Escalation Phase followed by a Cohort Expansion Phase All patients enrolled in the study were closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

In this agent, the anti-TIM-1 antibody covalently linked via via a valine-citrulline (vc) peptide linker, to a potent cytotoxin, monomethyl auristatin E (MMAE) using Seattle Genetics’ proprietary technology and designated as CDX-014.

In pre-clinical trials CDX-014 was shown to exhibit in vitro cytostatic or cytotoxic activity against a variety of TIM-1 expressing cell lines, but not on TIM-1 negative cell lines.[3]

The company is expected to focus clinical development on two company-sponsored programs—CDX-1140, a promising CD40 agonist, and CDX-3379, which blocks ErbB3, a receptor thought to play an important role in regulating cancer cell growth and survival.

“[The] development of varlilumab and CDX-301 will also continue externally through investigator-sponsored initiatives and internally through inclusion in combination studies,” Marucci added.

ADC-Development programs
With a number of other announcements made by various companies developing antibody-drug conjugates,  it is noteworthy to see that the majority of ADC-development programs being discontinued are in early phase I development (69%) and phase II (16%) development.[4]

While there there  is a relatively high number of ADC-development programs being cancelled, it is also noteworthy that there are nine new ADC-development programs that enter clinical trials this year.

Last Editorial Review: May 10, 2018

Featured Image: Doctor explaining clinical trial to patient. Courtesy: © 2018. Fotolia Used with permission.

Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Print Friendly, PDF & Email

Leave a Reply

Skip to toolbar